Cipla has allotted 17,064 fully paid-up equity shares of Rs 2 each, pursuant to exercise of employee stock options / stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,52,25,016 comprising of 80,76,12,508 equity shares of face value Rs 2 each. Powered by Capital Market - Live News

Net profit of Cipla rose 15.18% to Rs 1302.53 crore in the quarter ended September 2024 as against Rs 1130.91 crore during the previous quarter ended September 2023. Sales rose 5.65% to Rs 6961.22 crore in the quarter ended September 2024 as against Rs 6589.22 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales6961.226589.22 6 OPM %27.0926.31 - PBDT2060.801884.27 9 PBT1789.061594.23 12 NP1302.531130.91 15 Powered by Capital Market - Live News

Cipla announced that Cipla (EU), wholly owned subsidiary of the Company in UK has completed all the conditions with respect to acquisition of 6.9124% equity interest in Cipla (Jiangsu) Pharmaceuticals Co., China (Cipla Jiangsu) on 25 October 2024. Cipla Jiangsu is now a wholly owned step-down subsidiary of the Company. Powered by Capital Market - Live News

Cipla will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live News

Cipla announced that its wholly owned subsidiary in UK, Cipla (EU) has entered into a definitive agreement on 25 September 2024 for purchase of entire 6.9124% equity interest of Jiangsu Xidi Pharmaceuticals Co.(formerly known as Jiangsu Acebright Pharmaceuticals Co.) held in Cipla (Jiangsu) Pharmaceuticals Co., China (Cipla Jiangsu), subsidiary.Cipla Jiangsu was incorporated in China on 8th August 2019 as a joint venture between Cipla (EU) and Jiangsu XiDi Pharmaceuticals Co. (Xidi), for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services. Cipla Jiangsu has set-up a manufacturing facility in China, primarily focused on inhalation respules products. Currently, Cipla EU and Xidi holds 93.0876% and 6.9124% equity interest respectively in Cipla Jiangsu. Powered by Capital Market - Live News